Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,645Revenue $M0.0Net Margin (%)0Z-Score-7.2
Enterprise Value $M2,694EPS $-0.6Operating Margin %0F-Score5
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book010-y EBITDA Growth Rate %-16.6Quick Ratio0.6Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-27.6Current Ratio0.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-66.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M406ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MNKDJean-Marie Eveillard 2013-03-31 Sold Out -0.01%$2.31 - $3.56
($2.75)
$ 6.52137%Sold Out0
MNKDJean-Marie Eveillard 2012-12-31 Buy 0.01%$1.85 - $2.83
($2.16)
$ 6.52202%New holding, 800000 sh.800,000
MNKDGeorge Soros 2007-09-30 Sold Out -0.01%$8.87 - $13.09
($10.2)
$ 6.52-36%Sold Out0
MNKDGeorge Soros 2007-06-30 Buy 0.01%$11.46 - $14.95
($13.3)
$ 6.52-51%New holding, 13493 sh.13,493
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MNKD is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Thomson DavidVP & General Counsel 2015-02-19Sell68,662$7.19-5.15view
Edstrom HakanPresident & CEO 2015-02-10Sell73,460$7.75-12view
Thomson DavidVP & General Counsel 2015-02-05Sell80,000$7-2.57view
Palumbo DianeVice President, Human Resource 2015-02-05Sell149,833$6.95-1.87view
Edstrom HakanPresident & CEO 2015-01-30Sell73,460$6.347.57view
Palumbo DianeVice President, Human Resource 2015-01-05Sell188,999$5.9514.62view
Edstrom HakanPresident & COO 2014-12-01Sell74,668$5.8915.79view
Palumbo DianeVice President, Human Resource 2014-12-01Sell183,522$5.8915.79view
Martens JuergenCorporate VP 2014-11-24Sell140,000$6.1411.07view
Thomson DavidVP & General Counsel 2014-11-24Sell118,114$6.1411.07view

Press Releases about MNKD :

    Quarterly/Annual Reports about MNKD:

    News about MNKD:

    Articles On GuruFocus.com
    Portfolio 1 Jan 03 2015 
    What to Watch for: November 3-7 Nov 04 2014 
    Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
    There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 
    What This Upcoming Monday Means For MannKind Shareholders Aug 08 2014 
    Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 
    Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 


    More From Other Websites
    Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin Feb 27 2015
    Afrezza's Initial Sales Create Buying Opportunity Feb 27 2015
    Jefferies Expects Exciting 2015 For MannKind Feb 26 2015
    MannKind: 'Encouraged By Early Feedback' on Afrezza Launch Feb 26 2015
    MannKind Corporation to Present at the RBC Capital Markets Global Healthcare Conference Feb 25 2015
    MannKind: Nothing to See Here Feb 25 2015
    MannKind's Accounting Is 'Murky,' MLV Analyst Says Feb 25 2015
    MannKind Reports Narrower Y/Y Loss in Q4, Afrezza in Focus - Analyst Blog Feb 25 2015
    MannKind reports 4Q loss Feb 24 2015
    MannKind reports 4Q loss Feb 24 2015
    Mannkind Corp Earnings Call scheduled for 5:00 pm ET today Feb 24 2015
    MannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results Feb 24 2015
    MannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results Feb 24 2015
    MANNKIND CORP Files SEC form 8-K/A, Change in Directors or Principal Officers Feb 24 2015
    Q4 2014 Mannkind Corp Earnings Release - Before Market Open Feb 24 2015
    Afrezza Will Succeed But Initial Sales Likely To Disappoint Feb 20 2015
    Sales have been slower than expected. It takes time to educate the physician. Feb 20 2015
    MannKind Corporation to Present at the RBC Capital Markets Global Healthcare Conference Feb 18 2015
    MannKind Corporation to Hold 2014 Fourth Quarter and Full Year Financial Results Conference Call on... Feb 17 2015
    MannKind Corporation to Hold 2014 Fourth Quarter and Full Year Financial Results Conference Call on... Feb 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK